title: Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.
authors.affiliation: Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Santoni
authors.affiliation: Medical Oncology, 'G.B. Rossi' Academic Hospital, University of Verona, Verona, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Massari
authors.affiliation: Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D000818:Animals; D018821:CD18 Antigens / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002448:Cell Adhesion / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology; D016207:Cytokines / Q000378:metabolism; D000068338:Everolimus; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D011183:Postoperative Complications / Q000517:prevention & control*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D018821:CD18 Antigens; D016207:Cytokines; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D000068338:Everolimus; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus